company background image
ECX logo

Epigenomics DB:ECX Stock Report

Last Price

€1.76

Market Cap

€1.6m

7D

9.0%

1Y

-41.3%

Updated

26 Mar, 2024

Data

Company Financials +

Epigenomics AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Epigenomics
Historical stock prices
Current Share Price€1.76
52 Week High€5.25
52 Week Low€1.61
Beta0.99
1 Month Change3.83%
3 Month Change-6.13%
1 Year Change-41.33%
3 Year Change-96.17%
5 Year Change-99.41%
Change since IPO-99.71%

Recent News & Updates

Recent updates

Shareholder Returns

ECXDE BiotechsDE Market
7D9.0%3.3%1.6%
1Y-41.3%35.8%6.4%

Return vs Industry: ECX underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: ECX underperformed the German Market which returned 6.4% over the past year.

Price Volatility

Is ECX's price volatile compared to industry and market?
ECX volatility
ECX Average Weekly Movement6.5%
Biotechs Industry Average Movement5.9%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ECX has not had significant price volatility in the past 3 months.

Volatility Over Time: ECX's weekly volatility has decreased from 16% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199818Noel Dohenyhttps://www.epigenomics.com

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.

Epigenomics AG Fundamentals Summary

How do Epigenomics's earnings and revenue compare to its market cap?
ECX fundamental statistics
Market cap€1.59m
Earnings (TTM)-€4.46m
Revenue (TTM)€339.23k

4.7x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ECX income statement (TTM)
Revenue€339.23k
Cost of Revenue€56.91k
Gross Profit€282.32k
Other Expenses€4.75m
Earnings-€4.46m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

Sep 30, 2024

Earnings per share (EPS)-5.13
Gross Margin83.22%
Net Profit Margin-1,315.79%
Debt/Equity Ratio-148.3%

How did ECX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.